potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

It's NOT known for sure if these drugs increase cancer risk.

But they are immunosuppressants...and there are reports of skin and other cancers in patients using Protopic or Elidel.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote